Portal de recerca
- Inici /
- Projectes i Estudis Clínics /
- ESTUDIO EN FASE 2 PARA INVESTIGAR LA SEGURIDAD Y LA EFICACIA DE ABBV-105 ADMINISTRADO SOLO O EN COMBINACIÓN CON UPADACITINIB (COMBINACIÓN ABBV-599) CON UN TRATAMIENTO DE BASE CON FARME SINTÉTICOS CONVENCIONALES EN SUJETOS CON ARTRITIS REUMATOIDE ACTIVA CON RESPUESTA INSUFICIENTE O INTOLERANCIA A FARME BIOLÓGICOS.
ESTUDIO EN FASE 2 PARA INVESTIGAR LA SEGURIDAD Y LA EFICACIA DE ABBV-105 ADMINISTRADO SOLO O EN COMBINACIÓN CON UPADACITINIB (COMBINACIÓN ABBV-599) CON UN TRATAMIENTO DE BASE CON FARME SINTÉTICOS CONVENCIONALES EN SUJETOS CON ARTRITIS REUMATOIDE ACTIVA CON RESPUESTA INSUFICIENTE O INTOLERANCIA A FARME BIOLÓGICOS.
Dades bàsiques
- Protocol:
- M16-063
- EURDRACT:
- 2018-000666-10
- NCT:
- Centre:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Any inici:
- 2019
- Any de finalització:
- 2020
Documents
- No hi ha documents
Participants
-
José Andrés Román Ivorra
Investigador Principal
Grups d'Investigació
Finançadors - Promotors
Resultats de l'Assaig Clínic
Capítulo 10. Artritis psoriásica. Concepto, manifestaciones clínicas, analítica y radiología
FRAGIO, J.; (...); ROMÁN, J.
Capítulo de un Libro. 2019
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.09.006. 2024
18f-FDG-PET/CT for Giant Cell Arteritis Detection of Large Vessel Vasculitis: What Should We Take into Consideration? Analytical Study of the Arteser Registry
Estrada-Alarcon, Paula V.; (...); Blanco, Ricardo
Meeting Abstract. 2023
2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11611. 2021
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro
Article. 10.33393/grhta.2022.2333. 2022
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Zozaya, Neboa; (...); Verde, Luis
Article. 10.1017/S0266462322000459. 2022
A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.
de Andrés-Nogales F; (...); Martínez-Olmos J
Article. 10.1007/s41669-020-00201-2. 2020
A new definition and refocus of pharmaceutical care: the Barbate Document
Morillo-Verdugo R; (...); Poveda-Andrés JL
Article. 10.7399/fh.11389. 2020
Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients.
Fernández-Díaz C; (...); Blanco R
Article. 10.1093/rheumatology/keaa621. 2020
ABATACEPT IN MONOTHERAPY VERSUS COMBINED IN INTERSTITIAL LUNG DISEASE OF RHEUMATOID ARTHRITIS. MULTICENTER STUDY OF 263 CAUCASIAN PATIENTS
Fernandez-Diaz, C; (...); Blanco, R
Meeting Abstract. 10.1136/annrheumdis-2021-eular.892. 2021
ABATACEPT IN MONOTHERAPY VERSUS COMBINED IN INTERSTITIAL LUNG DISEASE OF RHEUMATOID ARTHRITIS. MULTICENTER STUDY OF 263 CAUCASIAN PATIENTS.
Fernandez-Diaz, Carlos; (...); Spanish Collaborative Group of Interstitial Lung Disease Associated with Rheumat
Article. 10.1093/rheumatology/keab317. 2022
ABATACEPT IN RHEUMATOID ARTHRITIS WITH INTERSTITIAL LUNG DISEASE. A MULTICENTRE STUDY OF 181 PATIENTS
Fernandez-Diaz, C; (...); Blanco, R
Meeting Abstract. 10.1136/annrheumdis-2019-eular.6091. 2019
Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Retrospective Multicenter Study of 263 Patients
Fernandez-Diaz, C.; (...); Blanco, Ricardo
Meeting Abstract. 2019
ABATACEPT IN USUAL AND IN NON-SPECIFIC INTERSTITIAL PNEUMONIA ASSOCIATED TO RHEUMATOID ARTHRITIS. NATIONAL MULTICENTER STUDY OF 190 PATIENTS
Atienza-Mateo, B; (...); Blanco, R
Meeting Abstract. 10.1136/annrheumdis-2021-eular.711. 2021
Abatacept in Usual and in Non-Specific Interstitial Pneumonia Associated to Rheumatoid Arthritis. National Multicenter Study of 190 Patients
Atienza-Mateo, Belen; (...); Blanco, Ricardo
Meeting Abstract. 2021
Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis
Atienza-Mateo B; (...); Blanco R
Article. 10.1016/j.ejim.2023.08.025. 2024
Abatacetp in Spanish Patients with Arthritis Rheumatoid and Interstitial Lung Disease. Multicenter Study of 263 Patients
Fernandez-Diaz, C; (...); Blanco, R
Meeting Abstract. 2020
ACR/EULAR 2022 Classification Criteria Compared to the ACR 1990 Classification Criteria in the ARTESER Registry of Giant Cell Arteritis
De Miguel, Eugenio; (...); Blanco-Alonso, Ricardo
Meeting Abstract. 2024
ACUTE PARAPARESIS AS CLINICAL PRESENTATION OF VERTEBRAL OSTEOMYELITIS
Fragio-Gil, JJ; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.6662. 2019
Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.
Ballesta-López O; (...); Poveda-Andrés JL
Article. 10.1177/1078155220915953. 2020
After JAK Inhibitor Failure, "Switching" or "Cycling"?
Munoz Martinez, Pablo Francisco; (...); Roman Ivorra, Jose Andres
Meeting Abstract. 2023
AFTER JAK INHIBITOR FAILURE, 'SWITCHING' OR 'CYCLING'?
Munoz Martinez, P.; (...); Roman Ivorra, J. A.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.4124. 2023
Analysing criteria for price and reimbursement of orphan drugs in Spain.
Badia, X; (...); Tort, M
Article. 10.7399/fh.11147. 2019
Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital
Valero García S; (...); Poveda Andrés JL
Article. 10.1177/10781552211038518. 2021
ANNALYSIS OF PRO-INFLAMMATORY BIOMARKERS IN A POLYMYALGIA RHEUMATICA COHORT DURING THE ACUTE ONSET OF THE DISEASE
Sanjuan, FMO; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2021-eular.3114. 2021
ANTIMALARIAL DRUGS AND ELECTROCARDIOGRAPHIC ALTERATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.
Barcena, C. Riesco; (...); Roman Ivorra, J. A.
Meeting Abstract. 10.1136/annrheumdis-2022-eular.2847. 2022
Apremilast in Combination vs Monotherapy for Refractory Oral And/or Genital Ulcers in Behcet's Disease: National Multicenter Study of 51 Cases
Atienza-Mateo, Belen; (...); Blanco, Ricardo
Meeting Abstract. 2019
APREMILAST IN MONOTHERAPY OR COMBINED IN NON-ULCER MANIFESTATIONS OF BEHCET'S DISEASE. NATIONAL MULTICENTER STUDY OF 34 REFRACTORY CASES OF CLINICAL PRACTICE
Morant, AH; (...); Blanco, R.
Meeting Abstract. 10.1136/annrheumdis-2020-eular.4720. 2020
Apremilast in refractory orogenital ulcers and other manifestations of Behcet's disease. A national multicentre study of 51 cases in clinical practice
Atienza-Mateo, B.; (...); Blanco, R.
Article. 2020
Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice.
Atienza-Mateo B; (...); Blanco R
Article. 2020
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis
Martinez Calabuig, Pablo; (...); Roman-Ivorra, Jose A.
Meeting Abstract. 2024
AUTOANTIBODY PROFILE ANALYSIS AND ITS ASSOCIATION WITH CLINICAL MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5699. 2019
Autologous stem cell transplantation in systemic sclerosis: 4 cases.
de la Rubia Navarro, Marta, Leal Rodriguez, Samuel, Roman Ivorra, Jose Andres
Article. 10.1016/j.reumae.2025.501810. 2025
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.
Iglesias Gómez R; (...); Poveda Andrés JL
Article. 10.1136/ejhpharm-2021-002741. 2021
BASELINE PROFILE OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS ON TREATMENT WITH BELIMUMAB OF A SPANISH MULTICENTER COHORT
Altabas Gonzalez, I.; (...); Rua-Figueroa, I.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.3003. 2023
BELIMUMAB IV EFFECT IN GLUCOCORTICOID TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
Navarro, MD; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.6585. 2019
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Fernandez Rivera C; (...); Hernandez D
Article. 10.1111/ctr.14550. 2022
Cardiovascular Risk Assessment with Carotid Ultrasonography in Addition to the Traditional Cardiovascular Risk Factor in Rheumatoid Arthritis: A Case Control Study
Mazario, RG; (...); Ivorra, JAR
Meeting Abstract. 2020
CARDIOVASCULAR RISK ASSESSMENT WITH CAROTID ULTRASONOGRAPHY IN ADDITION TO THE TRADITIONAL CARDIOVASCULAR RISK FACTORS IN RHEUMATOID ARTHRITIS PATIENTS: A CASE CONTROL STUDY
Mazario, RG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2020-eular.6420. 2020
Cardiovascular risk assessment with carotid ultrasound in rheumatoid arthritis.
González Mazarío R; (...); Román Ivorra JA
Article. 10.1016/j.medcli.2022.01.017. 2022
CLINICAL AND SEROLOGICAL EVOLUTION OF RHEUMATIC PATIENTS INFECTED BY SARS-COV-2
Navarro, M. De la Rubia; (...); Ivorra, J. A. Roman
Meeting Abstract. 10.1136/annrheumdis-2022-eular.4559. 2022
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model
Nogueras, A; (...); Calleja, MA
Letter. 10.1136/ejhpharm-2019-001905. 2019
Clinical trials: their contribution to the efficiency of the clinical management of rheumatoid arthritis.
Escandell CPA, Ivorra JAR
Article. 10.7573/dic.212612. 2019
CLINICAL VARIABILITY IN PATIENTS DIAGNOSED OF JUVENILE IDIOPATHIC ARTHRITIS WITH POSITIVE AND NEGATIVE ANTINUCLEAR ANTIBODIES (ANA)
Torrat Noves, A. M.; (...); Roman Ivorra, J. A.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.5203. 2023
COMORBIDITY CLUSTERS AND THEIR RELATIONSHIP WITH SEVERITY AND OUTCOMES OF THE INDEX DISEASES, IN A LARGE MULTICENTER SYSTEMIC LUPUS ERYTHEMATOSUS COHORT (RELESSER REGISTER)
Rua-Figueroa, I.; (...); Pego-Reigosa, J. M.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.4168. 2023
Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo
Megias-Vericat, JE; (...); Poveda, JL
Meeting Abstract. 2020
COMPUTER TOMOGRAPHY GUIDED BIOPSY YIELD IN PYOGENIC VERTEBRAL OSTEOMYELITIS. AN EXAMINATION OF INFLUENCING FACTORS
Fragio-Gil, JJ; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.6627. 2019
Concordance Between the QuantiFERON-TB Gold In-Tube and Tuberculin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Rheumatic Diseases
Perales, CP; (...); Ivorra, JAR
Meeting Abstract. 2020
CONCORDANCE BETWEEN THE QUANTIFERON-TB GOLD IN-TUBE AND TUBERCULIN TEST FOR THE DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH RHEUMATIC DISEASES
Perales, CP; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2021-eular.3157. 2021
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada
Article. 10.1016/j.farma.2023.04.002. 2023
CORRELATION BETWEEN PATIENT-REPORTED OUTCOMES OF HEALTH-RELATED QUALITY OF LIFE AND CLINICAL ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5661. 2019
Corrigendum to "Relationship between structural damage with loss of strength and functional disability in psoriatic arthritis patients" [Clin. Biomech. volume 68 (2019) Pages 169-174/Article Number JCLB 4795].
Olmos CMF; (...); Ivorra JAR
Correction. 10.1016/j.clinbiomech.2019.10.023. 2020
COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA
Gironella, M.; (...); Oyaguez, I
Meeting Abstract. 2019
COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN
Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.
Meeting Abstract. 2024
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
Poveda JL; (...); Torres C
Article. 10.1080/14737167.2019.1635014. 2020
COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN
Bonanad, S; (...); Gonzalez-Dominguez, A
Meeting Abstract. 2020
Costs of the management of hemophilia A with inhibitors in Spain
Bonanad, S; (...); Gonzalez-Dominguez, A
Article. 10.33393/grhta.2021.2234. 2021
COVID-19 AND JAKI: ANALYSIS AFTER THREE-YEAR PANDEMIC AT A SPANISH TERTIARY CARE HOSPITAL
Munoz Martinez, P.; (...); Roman Ivorra, J. A.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.4263. 2023
Cranial and extracranial giant cell arteritis do not exhibit differences in the IL6 -174 G/C gene polymorphism.
Genre, F.; (...); Gonzalez-Gay, M. A.
Article. 10.55563/clinexprheumatol/cbjnmo. 2023
Cranial and extracranial giant cell arteritis share similar HLA-DRB1 association
Prieto-Pena, D; (...); Gonzalez-Gay, MA
Article. 10.1016/j.semarthrit.2020.07.004. 2020
Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1111/hae.13733. 2019
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
Eduardo Megias, Juan; (...); Iorio, Alfonso
Meeting Abstract. 10.1182/blood-2019-127946. 2019
CT GUIDED NEEDLE BIOPSY IN VERTEBRAL OSTEOMYELITIS: RELIABILITY ANALYSIS AND STUDY OF WHICH FACTORS COULD INFLUENCE ON THE RESULT
Fragio-Gil, J. J.; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2020-eular.6383. 2020
CT-Guided Needle Biopsy in Vertebral Osteomyelitis: Study of Factors That Could Influence in Culture Yield.
Fragío Gil JJ; (...); Román Ivorra JA
Article. 10.1016/j.reumae.2020.08.007. 2022
CT-Guided Needle Biopsy in Vertebral Osteomyelitis: Study of Factors That Could Influence in Culture Yield
Fragio Gil, Jorge Juan; (...); Roman Ivorra, Jose Andres
Article. 10.1016/j.reuma.2020.08.002. 2022
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
Decreased DNA hydroxymethylation and increased DNA demethylation are associated with high antioxidant response in systemic lupus erythematosus patients.
Fragío Gil JJ; (...); Román Ivorra JA
Case Reports. 10.1016/j.medcli.2020.10.023. 2021
Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.
Salinas P; (...); Escaned J
Article. 10.1016/j.carrev.2021.11.015. 2021
Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis
Alvarez-Roman, MT; (...); Badia, X
Article. 10.1177/2284240319880534. 2019
DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
Alvarez, E.; (...); Badia, F. J.
Meeting Abstract. 2019
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN
Poveda, J. L.; (...); Vitoria, I
Meeting Abstract. 2019
Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain
Badia, X; (...); Poved, JL
Article. 10.1080/21678707.2019.1652163. 2019
Development of an application for mobile phones (App) based on the collaboration between the Spanish Society of Rheumatology and Spanish Society of Family Medicine for the referral of systemic autoimmune diseases from primary care to rheumatology.
Urruticoechea-Arana A; (...); Rúa-Figueroa Í
Article. 10.1016/j.reuma.2019.09.001. 2019
Diagnosis of Giant Cell Arteritis in Spain: Data from the ARTESER Registry
De Miguel, Eugenio; (...); Blanco, Ricardo
Meeting Abstract. 2021
Do antiTNF or Ustekinumab trough levels correlate with joint extraintestinal manifestations activity in Inflammatory bowel disease patients?
Madero Velazquez, L.; (...); Gutierrez Casbas, A.
Meeting Abstract. 2024
Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?
Madero Velazquez, L.; (...); Gutierrez Casbas, A.
Meeting Abstract. 2023
Efectiveness of belimumab in the treatment of lupus nephritis: analysis of 8 cases.
de la Rubia Navarro, Marta; (...); Roman Ivorra, Jose Andres
Article. 10.1016/j.medcli.2022.05.003. 2022
Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.
Torres Martínez E; (...); Vento M
Article. 10.1016/j.anpedi.2020.03.009. 2020
Effect of different schemes of androgen deprivation therapy on bone mass density in prostate cancer patients.
Arevalo Ruales, Karla; (...); Roman Ivorra, Jose Andres
Article. 10.1016/j.medcli.2022.03.026. 2023
EFFECTIVENESS OF BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS OF A MULTICENTER SPANISH COHORT
Altabas Gonzalez, I.; (...); Rua-Figueroa, I.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.3482. 2023
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
Palanques-Pastor T; (...); Poveda Andrés JL
Article. 10.1159/000517813. 2021
Effectiveness of Tocilizumab in Cranial and Extracranial Phenotypes of Giant Cell Arteritis: Multicenter Study of 471 Cases
Sanchez-Bilbao, Lara; (...); Blanco, Ricardo
Meeting Abstract. 2021
Effectiveness of Tocilizumab in the Visual Involvement of Giant Cell Arteritis: Multicenter Study of 471 Patients of Clinical Practice
Sanchez-Bilbao, Lara; (...); Blanco, Ricardo
Meeting Abstract. 2021
EFFICACY AND SAFETY OF APREMILAST IN BEHCET DISEASE PATIENTS
Bernabeu, EV; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2020-eular.5330. 2020
EFFICACY AND SAFETY OF BARICITINIB AND TOFACITINIB IN RHEUMATOID ARTHRITIS: DATA FROM REAL-WORLD
Mazario, RG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2020-eular.6321. 2020
Efficacy of Tocilizumab in Giant Cell Arteritis, Independent of the Time of Disease Evolution
Calderon-Goercke, Monica; (...); Blanco, Ricardo
Meeting Abstract. 2019
Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study
Pablos, JL; (...); Rivero, N
Article. 2019
Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus
Blanco, Ricardo; (...); Alvaro-Gracias, Jose Maria
Meeting Abstract. 2023
EPIDEMIOLOGY, DIAGNOSIS AND CLINICAL CHARACTERISTICS OF GIANT CELL ARTERITIS IN PATIENTS INCLUDED IN THE ARTESER MULTICENTER STUDY
Sanchez-Costa, J. T.; (...); Blanco, R.
Meeting Abstract. 10.1136/annrheumdis-2022-eular.1313. 2022
Erratum corrige: "Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study". J.L. Pablos et al.
Pablos JL; (...); Rivero N
Correction. 2020
EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN
Badia, F. J.; (...); Shepherd, J.
Meeting Abstract. 2019
EXPERIENCE IN REAL-WORLD CONDITIONS OF THE EFFECTIVENESS OFTHEVACCINE AGAINST HERPES ZOSTER
Mas Sanchez, L.; (...); Roman Ivorra, J. A.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.4258. 2023
EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY
F, de Andres-Nogales; (...); Martinez, M.
Meeting Abstract. 2019
Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report
Fernandez-Sanchez, M; (...); Poveda-Andres, JL
Article. 10.1002/bdr2.1942. 2021
FREQUENCY OF POLYAUTOIMMUNITY IN A TERTIARY HOSPITAL
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5582. 2019
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
Genotype FBN1/Phenotype relationship in a cohort of patients with Marfan syndrome.
Hernándiz A; (...); Sepúlveda P
Article. 10.1111/cge.13879. 2020
Giant Cell Arteritis Subtypes: Data from the ARTESER Registry
De Miguel, Eugenio; (...); Blanco, Ricardo
Meeting Abstract. 2021
Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease: Relation with Neoplasms and Role as a Paraneoplastic Syndrome
Munoz Martinez, Pablo; (...); Roman-Ivorra, Jose A.
Meeting Abstract. 2024
Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis
Editorial Material. 2022
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways
Lopez-Isac, E; (...); ASIG
Article. 10.1038/s41467-019-12760-y. 2019
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
Health-related quality of life in patients with systemic lupus erythematosus: a Spanish study based on patient reports
Ivorra, JAR; (...); Vivas-Consuelo, D
Article. 10.1007/s10067-019-04485-6. 2019
HEALTH-RELATED QUALITY OF LIFE MEASURES IN SPONDYLOARTHROPATY PATIENTS UNDER BIOLOGICAL THERAPIES IN REAL LIFE
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2021-eular.2282. 2021
High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.
El-Qutob D; (...); Carrera-Hueso FJ
Article. 10.1016/j.hrtlng.2022.02.003. 2022
Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies
Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo
Article. 10.7399/fh.11729. 2022
Hospitalization budget impact during the COVID-19 pandemic in Spain.
Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.
Article. 10.1186/s13561-021-00340-0. 2021
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
Hyperparathyroidism in patients with low bone mineral density treated with zoledronic acid or denosumab.
Riesco-Bárcena C; (...); Román-Ivorra J
Article. 10.1016/j.medcli.2024.07.020. 2024
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
IMPACT OF GENDER IN JAK INHIBITORS PRESCRIPTION: ANALYSIS FROM A SINGLE CENTER COHORT
Garcia, E. Grau; (...); Ivorra, J. A. Roman
Meeting Abstract. 10.1136/annrheumdis-2022-eular.3917. 2022
Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
Badia X; (...); Hernández C
Article. 10.1186/s13023-020-01507-4. 2020
Impact of voriconazole plasma concentrations on treatment response in critically ill patients
Ruiz, J; (...); Ramirez, P
Article. 10.1111/jcpt.12817. 2019
Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases
Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL
Article. 10.7399/fh.11262. 2020
Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register.
Fernandez-Lozano, Delia; (...); Blanco, Ricardo
Article. 10.1136/rmdopen-2023-003824. 2024
Incidence and General Clinical Features of Giant Cell Arteritis in the ARTESER Multicenter Study
Sanchez-Costa, Jesus T.; (...); Blanco, Ricardo
Meeting Abstract. 2021
Incidence of Hyperparathyroidism in Patients with Osteoporosis Treated with Zoledronic Acid or Denosumab
Riesco Barcena, Carmen; (...); Roman Ivorra, Jose Andres
Meeting Abstract. 2023
Increase of IL10 and IFNa2 Are Associated to Clinical Activity in Systemic Lupus Erythematous Patients
Grau Garcia, Elena; (...); Roman-Ivorra, Jose A.
Meeting Abstract. 2024
Increased interferon-1a, interleukin-10 and BLyS concentrations as clinical activity biomarkers in systemic lupus erythematosus.
Fernández Matilla M; (...); Román Ivorra JA
Article. 10.1016/j.medcli.2018.12.012. 2019
Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy
Bastida, G; (...); Nos, P
Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register
De Miguel, Eugenio; (...); Blanco, Ricardo
Article. 10.1136/rmdopen-2022-002507. 2022
Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register (vol 8, e002507, 2022)
De Miguel, Eugenio; (...); Blanco, Ricardo
Correction. 10.1136/rmdopen-2022-002507corr1. 2023
Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report
Company-Albir, MJ; (...); Poveda, JL
Article. 10.1111/jcpt.12842. 2019
Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.
Solana-Altabella A; (...); Poveda JL
Article. 10.1177/1078155220904410. 2020
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP
Article. 10.1136/ejhpharm-2020-002322. 2020
Is Belimumab Dose Optimization Possible in Patients with Systemic Lupus Erythematosus?: Analysis of This Therapeutic Strategy in a Large Multicenter Cohort of Patients from Spanish Rheumatology Departments
Altabas Gonzalez, Irene; (...); Rua-Figueroa, Inigo
Meeting Abstract. 2023
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
Pozo-Rosich P; (...); Irimia P
Article. 10.1186/s10194-024-01747-w. 2024
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula
Article. 10.3390/antibiotics13080706. 2024
JAK inhibitors in combination with anti-TNF drugs on difficult-to-treat chronic polyarthritis: a case series.
Leal S; (...); Román-Ivorra JA
Letter. 10.55563/clinexprheumatol/4ao14k. 2024
LAUDES Study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients.
Castellví I; (...); Fonollosa V
Article. 10.1007/s00296-019-04436-z. 2019
LONG-TERM FOLLOW-UP OF PRIMARY RAYNAUD'S PHENOMENON COHORT OF 248 PATIENTS
Sanjuan, FMO; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5989. 2019
Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.
Bykerk VP; (...); Sibilia J
Article. 10.1007/s10067-019-04535-z. 2019
LUPUS NEPHRITIS RESPONSE IN TERMS OF KIDNEY FUNCTION, URINE SEDIMENT AND SEROLOGICAL ACTIVITY AFTER SUBCUTANEOUS BELIMUMAB TREATMENT
De la Rubia Navarro, M.; (...); Ivorra, J. A. Roman
Meeting Abstract. 10.1136/annrheumdis-2022-eular.2944. 2022
Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.
Megías-Vericat JE; (...); Poveda-Andrés JL
Article. 2021
Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.
Vázquez Polo A; (...); Vázquez Costa JF
Article. 10.20960/nh.03946. 2022
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
Bonanad, S; (...); Santos, S
Article. 10.1007/s12325-021-01853-0. 2021
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Article. 10.3390/cancers14030596. 2022
Metyrapone as treatment in the neonatal McCune-Albright syndrome
de Mingo, Carmen; (...); Garcia-Robles, Ana
Article. 10.1515/jpem-2020-0036. 2020
Monitoring coagulation factors during surgery. A systematic review
Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11766. 2021
Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).
Valero-García S; (...); Delgado-Sánchez O
Article. 10.7399/fh.11655. 2021
Mortality in Patients with Giant Cell Arteritis in Spain: Results from the ARTESER Registry
Molina-Collada, Juan; (...); Blanco-Alonso, Ricardo
Meeting Abstract. 2024
Mortality in patients with giant cell arteritis in Spain: results from the ARTESER registry
Molina-Collada, Juan; (...); ARTESER Project Collaborative Grp, Clara
Article. 10.1186/s13075-024-03468-6. 2025
Multidisciplinary consensus on the use of hydroxychloroquine in patients with systemic lupus erythematosus
Rua-Figueroa, Inigo; (...); Calvo Alen, Jaime
Article. 10.1016/j.reuma.2024.03.005. 2024
Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments
Gomez-Cebrian, N; (...); Pineda-Lucena, A
Review. 10.3390/cancers13184544. 2021
Musculoskeletal Manifestations in Patients Diagnosed with Marfan Syndrome
Mas Sanchez, Laura; (...); Roman-Ivorra, Jose A.
Meeting Abstract. 2024
National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)
Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel
Correction. 10.7399/fh.11740. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
New structural insights into the role of TROVE2 complexes in the on-set and pathogenesis of systemic lupus erythematosus determined by a combination of QCM-D and DPI.
Juste-Dolz A; (...); Maquieira Á
Article. 10.1007/s00216-018-1407-x. 2019
Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer.
Zafra J; (...); Barragán I
Article. 10.3390/ijms25084533. 2024
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Real Life Study of 134 Patients
Calderon-Goercke, Monica; (...); Blanco, Ricardo
Meeting Abstract. 2019
OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT
Flores-Moreno, S.; (...); Gil, A.
Meeting Abstract. 2024
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol
Garcia-Robles, Ana; (...); Carrascosa, MA
Article. 10.3389/fped.2020.00372. 2020
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Correction. 10.3389/fped.2021.834454. 2022
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project
Morillo-Verdugo, R; (...); Diaz-Olmo, J
Article. 10.7399/fh.11719. 2021
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.
Morillo-Verdugo R; (...); Díaz-Olmo J
Article. 2021
Patient Decision Aid (PDA) for Patients with Rheumatoid Arthritis Reduces Decisional Conflict and Improves Readiness for Treatment Decision Making.
Pablos JL; (...); Lizán L
Article. 10.1007/s40271-019-00381-y. 2020
Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy
Margusino-Framiñán L; (...); Morillo-Verdugo R
Article. 10.7399/fh.11498. 2020
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Pharmacometabolomics by NMR in Oncology: A Systematic Review.
Gómez-Cebrián N; (...); Pineda-Lucena A
Article. 10.3390/ph14101015. 2021
Pharmacotherapeutic management of advanced therapy medicinal products
Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia
Article. 10.7399/fh.13036. 2022
PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS
Vericat, JEM; (...); Iorio, A
Meeting Abstract. 2020
PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019
Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.
García-Robles A; (...); Aguar-Carrascosa M
Letter. 10.1016/j.anpedi.2020.06.008. 2021
Preparation and administration of insulin infusions in neonatology: A national survey.
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Article. 10.1016/j.anpede.2020.06.015. 2021
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
Prevalence and clinical characteristics of patients with rheumatoid arthritis with interstitial lung disease using unstructured healthcare data and machine learning
Román Ivorra JA; (...); Castellanos-Moreira R
Article. 10.1136/rmdopen-2023-003353. 2024
PREVALENCE AND COMORBIDITIES OF RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN SPAIN: A RETROSPECTIVE ANALYSIS OF ELECTRONIC HEALTH RECORDS USING NATURAL LANGUAGE PROCESSING
Roman Ivorra, J. A.; (...); Lujan Valdes, S.
Meeting Abstract. 10.1136/annrheumdis-2022-eular.5042. 2022
PREVALENCE, DIAGNOSTIC DELAY AND TREATMENT PROFILE OF PATIENTS WITH MONOGENIC AUTOINFLAMMATORY DISEASES IN AN ADULT RHEUMATOLOGY SERVICE OF A TERTIARY HOSPITAL.
Perales, C. Pavez; (...); Ivorra, J. A. Roman
Meeting Abstract. 10.1136/annrheumdis-2022-eular.4143. 2022
Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review
Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11780. 2021
PROFILE OF REAL WORLD AXIAL SPONDYLOARTHRITIS PATIENTS REFRACTORY TO ADVANCED THERAPY
Alcantara Alvarez, I; (...); Roman Ivorra, J. A.
Meeting Abstract. 2024
PROFILE OF REFRACTORY RA PATIENTS FOR TARGETED THERAPIES IN REAL LIFE
Garcia, E. Grau; (...); Ivorra, J. A. Roman
Meeting Abstract. 10.1136/annrheumdis-2023-eular.4014. 2023
PROSPECTIVE STUDY OF 24 MONTHS OF EVOLUTION OF A COHORT OF PATIENTS WITH RHUPUS
Cordellat, I. Martinez; (...); Ivorra, J. A. Roman
Meeting Abstract. 10.1136/annrheumdis-2022-eular.3898. 2022
PROSPECTIVE STUDY OF BONE METABOLISM AND FRACTURE INCIDENCE IN SPINAL CORD INJURY PATIENTS DURING A PERIOD OF 24 MONTHS
Cordellat, IM; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5953. 2019
PULMONARY FUNCTION IN PATIENTS DIAGNOSED OF EARLY SYSTEMIC SCLEROSIS: 10 YEARS EXPERIENCE.
Ortiz-Sanjuan, F.; (...); Ivorra, J. A. Roman
Meeting Abstract. 10.1136/annrheumdis-2022-eular.3085. 2022
PULMONARY FUNCTION IN PATIENTS DIAGNOSED OF EARLY SYSTEMIC SCLEROSIS: A NEW TOOL FOR SYSTEMIC SCLEROSIS CLASIFFICATION?
Sanjuan, FMO; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2020-eular.4423. 2020
PULMONARY INVOLVEMENT AND FUNCTIONAL LIMITATION IN SYSTEMIC SCLEROSIS
Rodriguez, JEO; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.6576. 2019
REAL LIFE SAFETY AND SURVIVAL OF TARGETED THERAPIES IN ARTHRITIS PATIENTS OVER AGE OF 65
Grau Garcia, E.; (...); Roman Ivorra, J. A.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.3018. 2023
Real World Data on Antifibrotics in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients
Atienza-Mateo, Belen; (...); Blanco, Ricardo
Meeting Abstract. 2023
Real-world Effectiveness and Safety of JAK Inhibitors in Rheumatoid Arthritis: A Single-centre Study
Gonzalez Mazario, Roxana; (...); Roman Ivorra, Jose Andres
Article. 10.1016/j.reuma.2021.08.001. 2022
Real-world Effectiveness and Safety of JAK Inhibitors in Rheumatoid Arthritis: A Single-centre Study.
González Mazarío R; (...); Román Ivorra JA
Article. 10.1016/j.reumae.2021.08.004. 2022
Real-world evidence of tofacitinib in rheumatoid arthritis patients in Spain
Roman Ivorra, Jose A., Llevat, Noelia, Montoro, Maria
Article. 10.5582/ddt.2022.01028. 2022
Red flags for clinical suspicion of eosinophilic granulomatosis with polyangiitis (EGPA).
Solans-Laque, R; (...); Cid, M C
Article. 10.1016/j.ejim.2024.06.008. 2024
Refractory RA Patients for Targeted Therapies in Real Life
Grau Garcia, Elena; (...); Roman Ivorra, Jose Andres
Meeting Abstract. 2023
Relation Between Cumulative Damage in Systemic Lupus Erythematosus and Recognised Disability by the National Social Security Institute of Spain (INSS).
Fernández Matilla M; (...); Román Ivorra JA
Article. 10.1016/j.reuma.2019.03.003. 2019
Relationship between structural damage with loss of strength and functional disability in psoriatic arthritis patients.
Feced Olmos CM; (...); Román Ivorra JA
Article. 10.1016/j.clinbiomech.2019.06.009. 2019
RESPONSE OF BEHCET'S REFRACTORY ORAL AND/OR GENITAL ULCERS TO APREMILAST IN COMBINATION VS MONOTHERAPY. NATIONAL MULTICENTER STUDY OF 51 CASES OF CLINICAL PRACTICE
Morant, AH; (...); Blanco, R.
Meeting Abstract. 10.1136/annrheumdis-2020-eular.6246. 2020
Rhupus syndrome: Description of 9 cases with special attention to the HLA-DR genotype
Hurtado, Andres Perez; (...); Ivorraa, Jose Andres Roman
Article. 10.1016/j.medcli.2024.09.006. 2025
RITUXIMAB SAFETY AND PERSISTENCE IN PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES
Perales, CP; (...); Ivorra, JAR
Meeting Abstract. 2020
SCORE2 Is Superior to SCORE in Predicting the Presence of Carotid Plaques and Intima-media Thickness in Rheumatoid Arthritis Patients: A Cross-sectional Study with Carotid Ultrasound
Campos Fernandez, Cristina; (...); Roman-Ivorra, Jose A.
Meeting Abstract. 2024
SECONDARY PREVENTION OF VERTEBRAL FRACTURES SUSTAINED EFFICACY OVER TIME
Oller Rodriguez, J. E.; (...); Roman Ivorra, J. A.
Meeting Abstract. 10.1136/annrheumdis-2022-eular.3312. 2022
SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11565. 2020
Serological Evidence of SARS-CoV-2 in Symptomatic Patients Under Biological Treatment in a Rheumatology Service
Perales, CP; (...); Ivorra, JAR
Meeting Abstract. 2020
Sex Differences in Giant Cell Arteritis: Data from the ARTESER Registry
Fernandez-Lozano, Delia; (...); Blanco, Ricardo
Meeting Abstract. 2023
SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization
Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis
Article. 10.1111/jcpt.13703. 2022
Study of Bone Metabolism in Patients Diagnosed with Osteogenesis Imperfecta
Ramos Castro, Daniel; (...); Roman-Ivorra, Jose A.
Meeting Abstract. 2024
Sustained Drug-Free Remission in Giant Cell Arteritis.
Narvaez, Javier; (...); Blanco, Ricardo
Article. 10.1093/rheumatology/keae644. 2024
Sustained Drug-free Remission in Giant Cell Arteritis: Results Results of the Spanish ARTESER Registry
Narvaez-Garcia, Javier; (...); Blanco-Alonso, Ricardo
Meeting Abstract. 2024
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity
Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar
Article. 10.1007/s00431-022-04628-z. 2022
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; (...); Gil A
Article. 10.1016/j.yebeh.2022.108711. 2022
The impact of disease activity on health-related quality of life in patients with systemic lupus erythematosus.
Grau García E; (...); Román Ivorra JA
Article. 10.1016/j.medcli.2022.11.019. 2023
The presence of both HLA-DRB1*04:01 and HLA-B*15:01 increases the susceptibility to cranial and extracranial giant cell arteritis
Prieto-Pena, D; (...); Gonzalez-Gay, MA
Article. 2021
The presence of both HLA-DRB1[*]04:01 and HLA-B[*]15:01 increases the susceptibility to cranial and extracranial giant cell arteritis.
Prieto-Peña D; (...); González-Gay MA
Article. 2021
The role of 18F-FDG PET/CT in early infectious discitis: a case report after a negative MRI.
Fragío-Gil JJ; (...); Román-Ivorra JA
Case Reports. 10.1016/j.radcr.2019.04.006. 2019
THE ROLE OF CXCL4, CXCL8 AND GDF-15 IN SYSTEMIC SCLEROSIS
Rodriguez, JEO; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2020-eular.5019. 2020
The Role of Plasma Calprotectin in Non-infectious Uveitis.
Pascual EV; (...); Ivorra JAR
Article. 10.1080/02713683.2020.1867749. 2021
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Badia, Xavier; (...); Valles, Joan-Antoni
Article. 10.1186/s13023-024-03324-5. 2024
Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients.
Altabás-González I; (...); Rúa-Figueroa I
Article. 10.1093/rheumatology/kead696. 2024
TOCILIZUMAB FOR TAKAYASU ARTERITIS: MULTICENTER STUDY OF 54 WHITE PATIENTS
Prieto-Pena, D; (...); Blanco, R
Meeting Abstract. 10.1136/annrheumdis-2021-eular.1747. 2021
Tocilizumab in Caucasian Patients with Takayasu Arteritis: Multicenter Study of 54 Patients
Prieto-Pena, Diana; (...); Blanco, Ricardo
Meeting Abstract. 2021
Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice
Calderon-Goercke, M; (...); Blanco, R
Article. 10.1016/j.semarthrit.2019.01.003. 2019
Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice
Calderon-Goercke, M; (...); Blanco, R
Article. 2020
Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice.
Calderón-Goercke M; (...); Blanco R
Article. 2020
Tocilizumab in Giant Cell Arteritis: Route of Administration: Intravenous or Subcutaneous
Calderon-Goercke, Monica; (...); Blanco, Ricardo
Meeting Abstract. 2019
Tocilizumab in Giant Cell Arteritis: The Safest and Most Effective Initial Dose of Prednisone
Calderon-Goercke, Monica; (...); Blanco, Ricardo
Meeting Abstract. 2019
TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: MULTICENTRIC OBSERVATIONAL COMPARATIVE STUDY
Prieto-Pena, D.; (...); Blanco, R.
Meeting Abstract. 10.1136/annrheumdis-2022-eular.2330. 2022
Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review
Prieto-Pena, Diana; (...); Blanco, Ricardo
Article. 10.1177/1759720X211020917. 2021
Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.
Marques MR; (...); Mangas-Sanjuan V
Article. 10.1111/apa.14944. 2020
Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy
Del Rio-Bermudez, C; (...); Poveda, JL
Editorial Material. 10.1186/s40545-020-00276-6. 2020
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024
TRANSITIONAL CARE IN JUVENILE IDIOPATHIC ARTHRITIS: TIMING, PREVALENCE OF SUBTYPES AND TREATMENT PROFILE IN A SPANISH TERTIARY HOSPITAL.
Perales, C. Pavez; (...); Ivorra, J. A. Roman
Meeting Abstract. 10.1136/annrheumdis-2022-eular.4126. 2022
Treatment of Giant Cell Arteritis in the ARTESER Multicenter Study of 1675 Patients
Sanchez-Costa, Jesus T.; (...); Blanco, Ricardo
Meeting Abstract. 2021
TREATMENT WITH TOFACITINIB IN REFRACTORY PSORIATIC ARTHRITIS. MULTICENTER STUDY OF CLINICAL PRACTICE
Martin-Varillas, JL; (...); Blanco, R
Meeting Abstract. 10.1136/annrheumdis-2019-eular.7803. 2019
Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice.
Galíndez-Agirregoikoa E; (...); Tofacitinib PsA Clinical Practice Collaborative Group
Article. 10.3899/jrheum.201204. 2021
TREATMENT, ADVERSE EVENTS AND FOLLOW UP IN PATIENTS WITH GIANT CELL ARTERITIS IN THE ARTESER MULTICENTER STUDY
Sanchez-Costa, J. T.; (...); Blanco, R.
Article. 10.1136/annrheumdis-2022-eular.1314. 2022
Treat-to-Target Strategy in Patients with Rheumatoid Arthritis: Audit of Adherence from Real World Clinical Data.
Andréu JL; (...); Gil de Miguel Á
Article. 10.1016/j.reuma.2019.10.006. 2019
Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
Bejar, S; (...); Mateu, PN
Meeting Abstract. 2020
USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Dominguez Hernandez, L.; (...); Gomez Segui, I
Meeting Abstract. 2019
USE OF RITUXIMAB IN SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY AND DIFFUSE CUTANEOUS INVOLVEMENT. A SERIES OF 15 CASES
Ortiz Sanjuan, F.; (...); Roman Ivorra, J. A.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.2961. 2023
Utility of cytokines CXCL4, CXCL8 and GDF15 as biomarkers in systemic sclerosis.
Oller-Rodriguez, Jose E.; (...); Roman Ivorra, Jose A.
Article. 10.1016/j.medcli.2021.12.006. 2022
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023
Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype.
Prieto-Pena, D.; (...); Gonzalez-Gay, M. A.
Article. 10.55563/clinexprheumatol/8mku9c. 2022
VERTEBRAL OSTEOMYELITIS IN THE IMMUNOSUPPRESSED PATIENTS
Fragio-Gil, JJ; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.6621. 2019
Vertebral osteomyelitis: Clinical, microbiological and radiological characteristics of 116 patients
Gil, JJF; (...); Ivorra, JAR
Article. 10.1016/j.medcli.2019.12.029. 2020
Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis
Queiro, R; (...); Morla, R
Article. 10.3899/jrheum.180460. 2019
Visual Manifestations in Giant Cell Arteritis: Identification of Risk Factors from the ARTESER Registry
Molina-Collada, Juan; (...); Blanco, Ricardo
Meeting Abstract. 2023